Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients
Authors' conclusion
SAR 200 mg q2w showed significantly stronger inhibition of IL-6/STAT3 signalling than TCZ sc q2w but weaker inhibition than TCZ sc qw.
Study context
- Population
- Patients with rheumatoid arthritis (RA) who achieved low disease activity (CDAI≤10)
- Participants
- 8 / 8 / 7 / 8
- Exposure
- Tocilizumab (TCZ) 162 mg sc weekly vs TCZ 162 mg sc bi-weekly vs sarilumab (SAR) 200 mg sc bi-weekly vs MTX control
- TCZ qwn = 8
- TCZ q2wn = 8
- SAR q2wn = 7
- MTXn = 8reference
- Outcome
- Proportion of pSTAT3-positive CD4+ T cells after stimulation with 100 ng/ml recombinant human IL-6
Methodological detailsex vivo IL-6 stimulation of whole blood, phosflow cytometric analysis
- Ex vivo IL-6 stimulation of whole blood
- Phosflow cytometric analysis
Main finding
As reported in the abstract
pSTAT3-positive CD4+ T cells after 100 ng/ml IL-6 stimulation
Observational data: associations, not effects.
Original publication
Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and tocilizumab in rheumatoid arthritis patients. Clin Exp Rheumatol. Published 28 July 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →